August 14, 2011

Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Previous studies have defined a therapeutic area under the curve for mycophenolic acid (MPA) in the early post-transplant period, although the majority of centers do not perform routine MPA monitoring. This paper presents results of a randomized controlled trial comparing an initial higher dose of MPA to standard dosing in patients treated with steroids, cyclosporine +/- an interleukin-2 receptor antibody. MPA exposure was higher in the high-dose arm, and rejection rates were lower. There were no differences in patient or graft survival, follow-up was only six months, and these results may not apply to patients treated with tacrolimus or a lymphocyte-depleting antibody.

 

Renal Transplantation

Tags: , , , , ,